School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
PLoS One. 2024 Oct 29;19(10):e0308009. doi: 10.1371/journal.pone.0308009. eCollection 2024.
This study investigated the relationship between the long non-coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) expression and colorectal cancer (CRC) using a thorough systematic review and meta-analysis.
Under the PRISMA guidelines, a systematic review was conducted on studies published from the databases' inception to September 18, 2023. Prognostic value and diagnostic accuracy were explored. Additionally, the association between levels of MALAT1 expression and pathological features was investigated. The statistical analysis was performed using the "meta" package of R.
Among the pathological parameters examined, based on three studies involving 51 cases of metastatic CRC and 135 cases of non-metastatic CRC, a statistically significant correlation was found between the expression level of MALAT1 and distant metastasis, with an OR of 16.0118 (95% CI: 4.5618-56.2015). Three studies involving 378 cases reported overall survival and had a pooled HR of 2.3854 (95% CI: 1.3272-4.2875). Three studies involving 436 cases reported disease-free survival and had a pooled HR of 2.4772 (95% CI: 1.3774-4.4549). All prognosis studies utilized tumor tissue samples as specimens to assess the expression level of MALAT1. Case-to-control diagnostic studies with 126 cases and 126 controls had a pooled AUC value of 0.6173 (95% CI: 0.5436-0.6909), a pooled sensitivity of 0.675 (95% CI: 0.324-0.900), and a pooled specificity of 0.771 (95% CI: 0.685-0.839).
The expression of MALAT1 in CRC is highly correlated with distant metastasis and has an impact on survival and prognosis. MALAT1 could also be employed as a diagnostic biomarker. More prospective studies should be performed to assess the MALAT1 diagnostic potential in the early stages of CRC.
本研究通过全面的系统评价和荟萃分析，探讨长链非编码 RNA 肺癌转移相关转录本 1（MALAT1）表达与结直肠癌（CRC）之间的关系。
根据 PRISMA 指南，对从数据库建立到 2023 年 9 月 18 日发表的研究进行了系统评价。探讨了预后价值和诊断准确性，同时还研究了 MALAT1 表达水平与病理特征之间的关系。统计分析使用 R 中的“meta”包进行。
在检查的病理参数中，基于涉及 51 例转移性 CRC 和 135 例非转移性 CRC 的三项研究，发现 MALAT1 表达水平与远处转移之间存在统计学显著相关性，OR 为 16.0118（95%CI：4.5618-56.2015）。三项涉及 378 例病例的研究报告了总生存率，合并 HR 为 2.3854（95%CI：1.3272-4.2875）。三项涉及 436 例病例的研究报告了无病生存率，合并 HR 为 2.4772（95%CI：1.3774-4.4549）。所有预后研究均使用肿瘤组织样本作为标本评估 MALAT1 的表达水平。涉及 126 例病例和 126 例对照的病例对照诊断研究的合并 AUC 值为 0.6173（95%CI：0.5436-0.6909），合并敏感性为 0.675（95%CI：0.324-0.900），合并特异性为 0.771（95%CI：0.685-0.839）。
CRC 中 MALAT1 的表达与远处转移高度相关，对生存和预后有影响。MALAT1 也可作为诊断生物标志物。应开展更多的前瞻性研究，以评估 MALAT1 在 CRC 早期的诊断潜力。
